JNJ · Johnson & Johnson · Webcasts, Transcripts & Audio
$270.56
-2.64 (-0.97%)
At close · Nov 2
Return incl. dividend (before tax)
Q3 2026 earnings call transcript
Market Cap
$657.68B
Shares
2.41B
Volume · Nov 2
8.3M
Avg daily vol (3M)
6.92M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Johnson & Johnson Webcasts
Earnings calls, investor updates, investor days and conferences for Johnson & Johnson (JNJ), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-13
Johnson & Johnson (JNJ) Q3 2026 Earnings Call Transcript
Confident tone
Guidance and Outlook
Icotide Launch
MedTech Performance
Revenue
$25.40B
▲ 5.9% YoY Diluted EPS
$0.09
▼ 95.8% YoY Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Johnson & Johnson (JNJ) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Johnson & Johnson (JNJ) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-15
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript
Confident tone
Icotreke launch momentum
Inlexo bladder cancer launch
Tremphia / immunology growth
Revenue
$25.31B
▲ 6.6% YoY Diluted EPS
$2.27
▼ 0.9% YoY Gross margin
68.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Johnson & Johnson (JNJ) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-27
Johnson & Johnson (JNJ) May 27, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Johnson & Johnson (JNJ) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Johnson & Johnson (JNJ) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-14
Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript
Confident tone
Icotride (Iketide/Tremfya) launch in psoriatic disease
Inlexo (nadofaragene) bladder cancer launch and J-code
Pipeline catalysts and upcoming readouts
Revenue
$24.06B
▲ 9.9% YoY Diluted EPS
$2.14
▼ 52.9% YoY Gross margin
66.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Johnson & Johnson (JNJ) March 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-01-21
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Confident tone
MedTech product launches
2025 results and 2026 guidance
R&D pipeline and approvals
Revenue
$24.56B*
▲ 9.1% YoY Gross margin
67.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-14
Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript
Confident tone
MedTech performance and portfolio focus
Immunology (TREMFYA, icotrokinra)
Q3 operational sales growth across portfolio
Revenue
$23.99B
▲ 6.8% YoY Diluted EPS
$2.12
▲ 91% YoY Gross margin
69.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-16
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Confident tone
Medtech / Cardiovascular
Innovative Medicine / Oncology Growth
STELARA Loss of Exclusivity
Revenue
$23.74B
▲ 5.8% YoY Diluted EPS
$2.29
▲ 18.7% YoY Gross margin
67.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-15
Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
Confident tone
Diversified business resilience post-STELARA LOE
Tremfya IBD launch (UC and Crohn's)
Oncology portfolio momentum (DARZALEX, Rybrevant/Lazcluze)
Revenue
$21.89B
▲ 2.4% YoY Diluted EPS
$4.54
▲ 238.8% YoY Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-22
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Confident tone
MedTech performance and innovation
Innovative Medicine growth and pipeline
M&A and capital allocation
Revenue
$22.52B*
▲ 5.3% YoY Gross margin
68.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-15
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Confident tone
Innovative Medicine Growth
MedTech and Cardiovascular Expansion
Pipeline and Regulatory Approvals
Revenue
$22.47B
▲ 5.2% YoY Diluted EPS
$1.11
▼ 89.1% YoY Gross margin
69.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-17
Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript
Confident tone
MedTech Performance and Outlook
Innovative Medicine Growth and Pipeline
China and VBP Headwinds
Revenue
$22.45B
▲ 4.3% YoY Diluted EPS
$1.93
▼ 1.5% YoY Gross margin
69.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-16
Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript
Confident tone
MedTech operational performance
Multiple myeloma franchise
Innovative Medicine growth brands
Revenue
$21.38B
▲ 2.3% YoY Diluted EPS
$1.34
Gross margin
69.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-23
Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript
Confident tone
MedTech performance
CARVYKTI launch and manufacturing
M&A and capital allocation
Revenue
$21.39B
▲ 7.3% YoY Diluted EPS
$1.67
▲ 25.6% YoY Gross margin
68.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-17
Johnson & Johnson (JNJ) Q3 2023 Earnings Call Transcript
Revenue
$21.35B
▲ 6.8% YoY Diluted EPS
$10.21
▲ 507.7% YoY Gross margin
69.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-20
Johnson & Johnson (JNJ) Q2 2023 Earnings Call Transcript
Revenue
$21.52B
▲ 6.5% YoY Diluted EPS
$1.96
▲ 8.9% YoY Gross margin
70.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-18
Johnson & Johnson (JNJ) Q1 2023 Earnings Call Transcript
Revenue
$20.89B
▲ 5.3% YoY Diluted EPS
$-0.03
▼ 101.6% YoY Gross margin
68.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-24
Johnson & Johnson (JNJ) Q4 2022 Earnings Call Transcript
Revenue
$19.94B
▲ 104.1% YoY Diluted EPS
$1.33
Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-18
Johnson & Johnson (JNJ) Q3 2022 Earnings Call Transcript
Revenue
$20.00B
▼ 14.3% YoY Diluted EPS
$1.68
▲ 22.6% YoY Gross margin
69.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-19
Johnson & Johnson (JNJ) Q2 2022 Earnings Call Transcript
Revenue
$20.21B
▼ 13.3% YoY Diluted EPS
$1.80
▼ 23.4% YoY Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-19
Johnson & Johnson (JNJ) Q1 2022 Earnings Call Transcript
Revenue
$19.84B
▼ 11.1% YoY Diluted EPS
$1.93
▼ 16.8% YoY Gross margin
69.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-25
Johnson & Johnson (JNJ) Q4 2021 Earnings Call Transcript
Revenue
$9.77B*
▼ 56.5% YoY Gross margin
84.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-19
Johnson & Johnson (JNJ) Q3 2021 Earnings Call Transcript
Revenue
$23.34B
▲ 10.7% YoY Diluted EPS
$1.37
▲ 3% YoY Gross margin
68.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-21
Johnson & Johnson (JNJ) Q2 2021 Earnings Call Transcript
Revenue
$23.31B
▲ 27.1% YoY Diluted EPS
$2.35
▲ 72.8% YoY Gross margin
67.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-20
Johnson & Johnson (JNJ) Q1 2021 Earnings Call Transcript
Revenue
$22.32B
▲ 7.9% YoY Diluted EPS
$2.32
▲ 6.9% YoY Gross margin
68.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-26
Johnson & Johnson (JNJ) Q4 2020 Earnings Call Transcript
Revenue
$22.48B*
▲ 8.3% YoY Gross margin
65.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-13
Johnson & Johnson (JNJ) Q3 2020 Earnings Call Transcript
Revenue
$21.08B
▲ 1.7% YoY Diluted EPS
$1.33
▲ 101.5% YoY Gross margin
66.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-16
Johnson & Johnson (JNJ) Q2 2020 Earnings Call Transcript
Revenue
$18.34B
▼ 10.8% YoY Diluted EPS
$1.36
▼ 34.6% YoY Gross margin
64.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-14
Johnson & Johnson (JNJ) Q1 2020 Earnings Call Transcript
Revenue
$20.69B
▲ 3.3% YoY Diluted EPS
$2.17
▲ 56.1% YoY Gross margin
65.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-22
Johnson & Johnson (JNJ) Q4 2019 Earnings Call
Revenue
$20.75B
▲ 1.7% YoY Diluted EPS
$1.50
▲ 33.9% YoY Gross margin
65.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–35 of 35 webcasts
Key facts
CIK
200406
CUSIP
478160104
13F (30d)
2453 filings
2347 filers
Visit website
Investor relations